Latest news

• Elan buys into GSK-partnered Theravance programmes for $1bn

  Aside from Breo ( known as Relvar outside the US), Elan will get royalties on sales of COPD combination therapy Anoro ( umeclidinium bromide and vilanterol), vilanterol as a monotherapy and GSK961081, a

• EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

  Elsewhere, GSK followed up approval in Japan for its respiratory medicine Relvar Ellipta with a CHMP recommendation for use in asthma and COPD, while Plethora Solution's Lidocaine/ Prilocaine Plethora was backed

• Double asthma approval in Japan lifts SkyePharma

  The Japanese Ministry of Health, Labour and Welfare ( MHLW) cleared GlaxoSmithKline's ( GSK) Relvar Ellipta ( vilanterol and fluticasone), as well as Kyorin Pharmaceutical's Flutiform ( formoterol and fluticasone) for the treatment of bronchial

• FDA queries safety of GSK's Anoro for COPD

  Adviser questions the drug's cardiovascular profile

• GSK submits COPD drug in US and EU

  In addition to umeclidinium bromide and Anoro, GSK's planned products in respiratory include a combination of fluticasone furoate and vilanterol intended to be marketed as Relvar in Europe and Breo in